EMA-FDA-PMDA action + Podcasts (CDD, Pew) + NEJM on non-inferiority

Dear All: Several updates today, all on the theme of good things to know or share!

First, EMA, FDA, and PMDA are continuing to meet and have released a summary of their third tripartite meetingThe key message is alignment: alignment on trial designs for key indications, alignment on pediatric programs, and alignment on single global development programs! This is excellent to see and I look forward to hearing more about this during the 2018 meetings.

Second, CDD (Collaborative Drug Discovery) has released a podcast by Lynn Silver and Johannes Zuegg in which they survey ways to think about finding molecules for Gram-negatives that both penetrate and have reliable activity. CDD will also host a webinar on 13 Dec 2017 on BMGF’s TB Drug Accelerator program.

Third, a recent paper in NEJM by Mauri & D’Agostino provides a good survey of non-inferiority trial designs. you haven’t already done so, read as well the May 2017 Rex, Talbot, et al. paper in CID on non-inferiority designs specifically for antimicrobial agents. If you’re going to work in this area, you need an in-depth understanding of strengths and weaknesses of these trials and these papers provide the background you need.

Finally, our colleagues at Pew Trust have released a variety of materials that you may find useful personally or to share. These include a podcast, two Q&A documents, and a trio of patient vignettes. All these materials are suitable for helping tell the story of AMR to interested colleagues — the patient vignettes are brief (~5 minutes) and especially compelling.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Share

EPA (part 5): Interagency Framework on AMR Risks of Antibacterial and Antifungal Pesticides

This is the fifth of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, and a 4th newsletter (27 Jan 2024) containing some additional resources. Dear All, Excitingly, the US EPA

HLM on AMR at UNGA: The end of the beginning

Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. Dear All (and with thanks to Damiano for co-authoring), Last week in NYC, the UN General Assembly (UNGA) and all its surrounding activities created a lot of energy (not to mention a giant traffic jam)! After a series of side meetings

Without action, AMR costs go from $66b to $159b/yr by 2050

Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout

UN TV: You can watch the AMR High-Level Meeting at UNGA

Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today.  You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD

Scroll to Top